Skip to main content

Table 1 Participant demographics and baseline characteristics (SP)

From: Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study

Baseline characteristic TDF (N = 75)
Age (years), mean (± SD) 48.4 (± 9.35)
Sex, n (%)
 Male 55 (73)
 Female 20 (27)
Race, n (%)
 Japanese 71 (95)
 East Asian 4 (5)
HBV genotype, n (%)
 A 1 (1)
 B 2 (3)
 C 72 (96)
HBV-DNA (log10 IU/mL), mean (± SD) 0.92 (± 0.12)
ALT (IU/L), mean (± SD) 23.5 (± 18.13)
HBeAg, n (%)
 Positive 70 (93)
 Negativea 5 (7)
HBsAg (IU/mL), mean (± SD) 5311.3 (± 5619.84)
HBcrAg (log10 U/mL), mean (± SD) 5.5 (± 0.55)
eGFR by JSN-CKDI (mL/min/1.73m2), n (%)
 < 60 0 (0)
 60 to < 90 42 (56)
 ≥ 90 33 (44)
Urine beta-2-microglobulin (µg/g Cr), mean (± SD) 241.9 (305.58)
Protocol defined liver cirrhosis, n (%)
 Yes 0 (0)
 No 75 (100)
  1. ALT alanine aminotransferase, Cr creatinine, eGFR by JSN-CKDI estimated glomerular filtration rate calculated by the Japanese Society of Nephrology-Chronic Kidney Disease Initiatives equation, HBV hepatitis B virus, HBeAg hepatitis B e-antigen, HBsAg hepatitis B surface antigen, HBcrAg hepatitis B core-related antigen, SD standard deviation, SP safety population, TDF tenofovir disoproxil fumarate
  2. aHBeAg-positive according to local in-hospital laboratory results, but HBeAg-negative according to central laboratory results at screening